Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Advisory Panel Clears Sanofi’s Jevtana But Wants to Review Multaq’s Liver Risks

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis' cabazitaxel receives a positive opinion from the EU's scientific advisory committee, but the benefit/risk balance of the French company's anti-arrhythmic, Multaq, needs to be reviewed.

You may also be interested in...



EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe

While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.

EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe

While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.

Five Positive Opinions From EU's CHMP Brightens Up The New Year

New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.

Topics

UsernamePublicRestriction

Register

PS071727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel